Page last updated: 2024-10-16

adenine and Lassitude

adenine has been researched along with Lassitude in 12 studies

Research Excerpts

Excerpt	Relevance	Reference
"This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)."	9.27	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018)
"This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)."	5.27	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018)
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)."	2.90	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019)
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."	2.78	Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. ( Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013)

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (8.33)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	9 (75.00)	24.3611
2020's	2 (16.67)	2.80

Authors

Authors	Studies
Mayer, KH	1
Gelman, M	1
Holmes, J	1
Kraft, J	1
Melbourne, K	1
Mimiaga, MJ	1
Deering, KL	1
Sundaram, M	1
Harshaw, Q	1
Trudeau, J	1
Barrientos, JC	4
Cramer, P	1
Fraser, G	1
Santucci-Silva, R	1
Grosicki, S	2
Dilhuydy, MS	1
Janssens, A	2
Loscertales, J	1
Rule, S	1
Goy, A	1
Traina, S	1
Chan, EKH	1
Diels, J	1
Sengupta, N	1
Mahler, M	1
Salman, M	1
Howes, A	1
Chanan-Khan, A	1
Gribben, JG	1
Bosch, F	1
Cymbalista, F	2
Geisler, CH	1
Ghia, P	3
Hillmen, P	4
Moreno, C	3
Stilgenbauer, S	1
Chari, A	1
Larson, S	1
Holkova, B	1
Cornell, RF	1
Gasparetto, C	1
Karanes, C	1
Matous, JV	1
Niesvizky, R	1
Valent, J	1
Lunning, M	1
Usmani, SZ	1
Anderson, LD	1
Chang, L	1
Lee, Y	1
Pak, Y	1
Salman, Z	1
Graef, T	1
Bilotti, E	2
Chhabra, S	1
Coutre, SE	2
Byrd, JC	3
Barr, PM	3
Devereux, S	3
Robak, T	3
Kipps, TJ	3
Schuh, A	3
Furman, RR	3
Burger, JA	3
O'Dwyer, M	2
Valentino, R	1
Chang, S	1
Dean, JP	1
James, DF	4
O'Brien, SM	1
Ruane, PJ	1
DeJesus, E	1
Berger, D	1
Markowitz, M	1
Bredeek, UF	1
Callebaut, C	1
Zhong, L	1
Ramanathan, S	1
Rhee, MS	1
Fordyce, MW	1
Yale, K	1
Brown, JR	1
O'Brien, S	2
Kay, NE	1
Reddy, NM	1
Coutre, S	2
Tam, CS	2
Mulligan, SP	1
Jaeger, U	1
Pocock, C	1
Thornton, P	1
Caligaris-Cappio, F	1
Delgado, J	1
Schuster, SJ	1
Montillo, M	1
de Vos, S	2
Gill, D	1
Bloor, A	1
Dearden, C	1
Jones, JJ	1
Chu, AD	1
Fardis, M	1
McGreivy, J	1
Clow, F	2
Blum, KA	1
Coleman, M	2
Wierda, WG	1
Jones, JA	1
Zhao, W	1
Heerema, NA	1
Johnson, AJ	1
Shaw, Y	1
Zhou, C	1
Tedeschi, A	1
Owen, C	1
Bairey, O	1
Bartlett, NL	1
Li, J	1
Simpson, D	1
McCarthy, H	1
Quach, H	1
Gaidano, G	1
Maslyak, Z	1
Stevens, DA	1
Offner, F	1
Mayer, J	1
Hellmann, A	1
Siddiqi, T	1
Polliack, A	1
Suri, D	1
Cheng, M	1
Styles, L	1
Noy, A	1
Thieblemont, C	1
Martin, P	1
Flowers, CR	1
Morschhauser, F	1
Collins, GP	1
Ma, S	1
Peles, S	1
Smith, S	1
Smith, A	1
Munneke, B	1
Dimery, I	1
Beaupre, DM	1
Chen, R	1
KIRZON, MV	1
ALLIK, TA	1
SHESTAKOV, SV	1

Clinical Trials (15)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1[NCT03499483]	Phase 4	52 participants (Actual)	Interventional	2019-01-24	Completed
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069]	Phase 2	199 participants (Actual)	Interventional	2010-06-30	Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]	Phase 1/Phase 2	133 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]	Phase 3	391 participants (Actual)	Interventional	2012-06-30	Completed
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346]	Phase 3	232 participants (Actual)	Interventional	2012-08-28	Completed
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487]	Phase 3	269 participants (Actual)	Interventional	2013-03-31	Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]	Phase 4	10 participants (Actual)	Interventional	2018-01-08	Completed
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-04-11	Terminated (stopped due to Insufficient accrual)
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]		40 participants (Actual)	Observational [Patient Registry]	2018-12-01	Completed
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947]	Phase 2	3 participants (Actual)	Interventional	2018-12-01	Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]		40 participants (Actual)	Observational	2017-07-21	Active, not recruiting
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470]		92 participants (Anticipated)	Observational	2021-03-31	Not yet recruiting
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]	Phase 3	22 participants (Actual)	Interventional	2019-12-09	Active, not recruiting
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097]	Phase 2	15 participants (Anticipated)	Interventional	2022-10-30	Not yet recruiting
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628]	Phase 2	63 participants (Actual)	Interventional	2013-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Event

All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug

Intervention	Participants (Count of Participants)
IBRUTINIB/PCI-32765	42

Number of Subjects With Adverse Events

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

Intervention	Participants (Count of Participants)
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH	199

Progressive Disease (PD)

A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

Intervention	Participants (Count of Participants)
IBRUTINIB/PCI-32765	70

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention	(Number)
Food Effect Cohort	1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

Intervention	Participants (Number)
PCI-32765	116
Food Effect	11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

Intervention	Percentage of Participants (Number)
Treatment Naive	71
Relapsed/ Refractory	75.3
Food Effect	56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

Intervention	Percentage of Participants (Number)
Treatment Naive	96.3
Relapsed/ Refractory	73.6
Food- Effect	NA

OS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Intervention	months (Median)
Ofatumumab (Arm A)	65.1
Ibrutinib (Arm B)	67.7

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Intervention	percentage of participants (Number)
Ofatumumab (Arm A)	4.1
Ibrutinib (Arm B)	42.6

Overall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Intervention	percentage of participants (Number)
Ofatumumab (Arm A)	22.4
Ibrutinib (Arm B)	87.7

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Intervention	months (Median)
Ofatumumab (Arm A)	8.1
Ibrutinib (Arm B)	NA

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Intervention	months (Median)
Ofatumumab (Arm A)	8.1
Ibrutinib (Arm B)	44.1

Rate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Intervention	percentage of participants (Number)
	Hgb Improvement in patient with baseline anemia	Platelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)	69.7	78.4
Ofatumumab (Arm A)	32.6	9.4

ORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	percentage of participants (Number)
Ibrutinib	82.4
Chlorambucil	35.3

Overall Survival (OS)

OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	Months (Median)
Ibrutinib	NA
Chlorambucil	NA

PFS (Progression Free Survival)

"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	Months (Median)
Ibrutinib	NA
Chlorambucil	18.9

Proportion of Sustained Hemoglobin Improvement

The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	Percentage of Participants (Number)
Ibrutinib	45.6
Chlorambucil	20.3

Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	Percentage of Participants (Number)
Ibrutinib	84.3
Chlorambucil	45.5

Proportion of Sustained Platelet Improvement

The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	Percentage of Participants (Number)
Ibrutinib	27.2
Chlorambucil	11.3

Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

Intervention	Percentage of Participants (Number)
Ibrutinib	77.1
Chlorambucil	42.9

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Intervention	ng*h/mL (Geometric Mean)
TDF With a Boosted PI	3466
TAF With a Boosted PI	743
TAF With a Boosted PI and LDV/SOF	868

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Intervention	fmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI	36014
TAF With a Boosted PI	6735
TAF With a Boosted PI and LDV/SOF	6100

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Intervention	fmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI	83.0
TAF With a Boosted PI	926
TAF With a Boosted PI and LDV/SOF	1129

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Intervention	mL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI	86.7
TAF With a Boosted PI	91.0
TAF With a Boosted PI and LDV/SOF	88.1

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Intervention	mg/g (Geometric Mean)
TDF With a Boosted PI	134
TAF With a Boosted PI	118
TAF With a Boosted PI and LDV/SOF	97.3

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Intervention	ug/g (Geometric Mean)
	β2M:Cr ratio	RBP:Cr ratio
TAF With a Boosted PI	224	242
TAF With a Boosted PI and LDV/SOF	178	146
TDF With a Boosted PI	419	436

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

Intervention	Participants (Count of Participants)
Ibrutinib Plus Rituximab	0

DOR (Duration of Response)

The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

Intervention	Months (Median)
Ibrutinib	NA

ORR (Overall Response Rate)

"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

Intervention	Percentage of Participants (Mean)
Single Arm, Intent to Treat Population	46

Reviews

1 review available for adenine and Lassitude

Article	Year
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British journal of haematology, 2018, Volume: 180, Issue:5 Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus,	2018

Trials

7 trials available for adenine and Lassitude

Article	Year
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H Leukemia & lymphoma, 2018, Volume: 59, Issue:9 Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Bl	2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma, 2018, Volume: 59, Issue:11 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso	2018
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati	2019
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. Journal of acquired immune deficiency syndromes (1999), 2013, Aug-01, Volume: 63, Issue:4 Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug;	2013
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25 Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female	2015
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood, 2017, 04-20, Volume: 129, Issue:16 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic	2017

Other Studies

4 other studies available for adenine and Lassitude

Article	Year
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. Journal of acquired immune deficiency syndromes (1999), 2022, 05-01, Volume: 90, Issue:1 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3	2022
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study. PloS one, 2022, Volume: 17, Issue:10 Topics: Adenine; Cross-Sectional Studies; Fatigue; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient S	2022
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, Apr-16, Volume: 125, Issue:16 Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance	2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, Apr-16, Volume: 125, Issue:16 Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance	2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, Apr-16, Volume: 125, Issue:16 Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance	2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, Apr-16, Volume: 125, Issue:16 Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance	2015
[Biochemical characteristics of the skeletal muscles of frogs in different stages of fatigue following single stimulations of the nerve]. Biulleten' eksperimental'noi biologii i meditsiny, 1962, Volume: 54 Topics: Adenine; Adenosine Triphosphate; Coenzymes; Fatigue; Lactates; Muscle, Skeletal; Neuromuscular Junct	1962